References
- 1. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: A multidisciplinary approach to care. The Lancet. Neurology. 2014;13(8):834-843.
- 2. Rasmussen JM, Friedman S. NF1 gene and neurofibromatosis 1. American Journal of Epidemiology. 2000;151:33-40.
- 3. S Melmed, K Polonsky, P Larsen, H Kronenberg. Williams textbook of endocrinology: 12th ed. Philadelphia, Saunders Elsevier 2012;555-567.
- 4. Oates E, Bankoff MS, Vogelzang PJ. Parathyroid adenoma associated with neurofibromatosis: correlative scintigraphic and magnetic resonance imaging. Clin Nucl Med. 1989;14:168-70.
- 5. Bijou F, Vargas F, Valentino R, et al. Association of type 1 neurofibromatosis and primary hyperparathyroidism. Presse Med. 2002;31:1604-5.
- 6. Iihara M, Okamoto T, Obara T et al. Water-clear cell parathyroid adenoma causing primary hyperparathyroidism in a patient with neurofibromatosis type 1: report of a case. Surg Today. 2007;37:884-7.
- 7. Collicott PE, Stivrins TJ, Hoppe LB. Von Recklinghausen’s neurofibromatosis and primary hyperparathyroidism: a case report and literature review. Nebraska Medical Journal. 1986;1:435-7.
- 8. Kalkan E, Waguespack SG. Endocrine tumors associated with neurofibromatosis type 1, peutz-jeghers syndrome and other familial neoplasia syndromes. Frontiers of Hormone Research. 2013;41:166-181.
- 9. Heervae E, Leinonen P, Kuorilehto T et al. Neurofibromatosis 1-Related Osteopenia Often Progresses to Osteoporosis in 12 Years. Calcified Tissue International. 2013;92:23-27.
- 10. Al-Wahhabi B. Parathyroid adenoma and bilateral pheochromocytoma in a patient with neurofibromatosis. Ann Saudi Med. 2005;25:255-257.
- 11. Sabatini C, Milani D, Menni F, Tadini G, Esposito S. Treatment of neurofibromatosis type 1. Current treatment options in neurology. 2015;17(6):355-360
- 12. Gurleyik F, Ocak C, Bahadir D. Neurofirbomatosis type 1 and primary hyperparathyroidism with spinal deformity and osteoporosis. Acta Chir Belg. 2009;109:123-5.
- 13. Gkaliagkousi E, Erlic Z, Petidis K et al. Neurofibromatosis type 1: should we screen for other genetic syndromes? A case report of co-existence with multiple endocrine neoplasia 2A. Eur J Clin Invest. 2009;39:828-832.
- 14. Diliberti JH, Andrews AM, Buist N et al. Myotonic dystrophy and hyperparathyroidism: association with neurofibromatosis and multiple endocrine adenomatosis type 2A. J Neurol Neurosurg Psychiatry. 1988;51:1578-1580.
- 15. Madson Q, Stratakis CA. Solid tumors associated with multiple endocrine neoplasias. Cancer genetics and cytogenetics. 2010;203:30-36.
- 16. Toruner F, Cimen AR, Karakoc A et al. The association of neurofibromatosis, bilateral pheochromocytoma and primary hyperparathyroidism. Exp Clin Endocrinol Diabetes. 2007;115:48-70.
- 17. De Lellis RA, Lloyd RV, Heitz PU. Pathology and genetics: tumours and endocrine organs. 3rd ed. Geneva: WHO, 2004.
- 18. Edmund S, Cibas SZ. The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2009;13:658-665.
- 19. Rosai J, LiVolsi VA, Sobrinho-Simoes M et al. Renaming papillary microcarcinoma of the thyroid gland: the Porto proposal. Int J Surg Pathol. 2003;11:249-251.
- 20. Véronique Hofman, Sandra Lassalle, Christelle Bonnetaud et al. Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility. Virchows Arch. 2009;455(1):21-33.
- 21. Fatma El-Zahraa, Salah El-Deen Yassin. Diagnostic criteria of well differentiated thyroid tumor of uncertain malignant potential; a histomorphological and immunohistochemical appraisal. Journal of the Egyptian National Cancer Institute. 2015;27(2):59-67.
- 22. Nechifor-Boila A, Borda A, Sassolas G et al. Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases. Pathol Res Pract. 2015;211(4):320-5.
- 23. Arora N, Scognamiglio T, Lubitz CC et al. Identification of borderline thyroid tumors by gene expression array analysis. Cancer. 2009;115:5421-31.
- 24. Baloch ZW, LiVolsi VA. Our approach to follicular-patterned lesions of the thyroid. J Clin Pathol. 2007;60:244-50.